Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

XORTX Therapeutics Inc

Healthcare CA XRTX

2.9CAD
0.08(2.84%)

Last update at 2026-06-05T20:00:00Z

Day Range

2.902.90
LowHigh

52 Week Range

2.429.85
LowHigh

Fundamentals

  • Previous Close 2.82
  • Market Cap6.03M
  • Volume100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.50849M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.65630M -3.31335M -2.15807M -6.98888M -1.65228M
Minority interest - - - - -
Net income -2.65630M -3.31335M -2.15807M -6.98888M -1.65228M
Selling general administrative 1.83M 2.28M 2.23M 2.29M 2.78M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.11M 0.12M 0.14M 0.06M 0.02M
Ebit - - - -12.02753M -2.89411M
Ebitda - - - -6.93342M -1.62880M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -3.25601M -4.11832M -6.04599M -9.86225M -3.64952M
Other operating expenses - - - - -
Interest expense - - - 0.00000M 0.00560M
Tax provision - - - - -
Interest income 0.04M - 0.26M 0.10M -
Net interest income 0.04M 0.12M 0.25M -0.82535M -1.62928M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 3.26M 4.12M 6.05M 9.86M 3.65M
Cost of revenue - - - - -
Total other income expense net 0.56M 0.68M 3.63M 3.70M 3.63M
Discontinued operations - - - - -
Net income from continuing ops -2.65630M -3.31335M -2.15807M -6.98888M -1.65228M
Net income applicable to common shares - - - -9.48531M -1.65228M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.68M 4.09M 5.47M 12.34M 22.04M
Intangible assets 0.19M 0.18M 0.18M 0.20M 0.26M
Earning assets - - - - -
Other current assets - - - - 0.71M
Total liab 0.60M 0.76M 0.83M 5.37M 5.30M
Total stockholder equity 2.08M 3.34M 4.64M 6.97M 16.74M
Deferred long term liab - - - - -
Other current liab 0.00800M 0.57M - - 4.60M
Common stock - - - 20.61M 20.01M
Capital stock 20.18M 18.49M 17.06M 15.18M 20.01M
Retained earnings -23.82456M -21.16825M -17.85491M -19.17559M -9.69028M
Other liab - - - 5.22M 4.60M
Good will - - - - -
Other assets - - - 1.61M 1.61M
Cash 0.86M 2.47M 3.45M 10.41M 18.85M
Cash and equivalents - - - - -
Total current liabilities 0.60M 0.76M 0.29M 2.05M 0.70M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - 8.04M 6.42M
Property plant equipment - - - 0.13M -
Total current assets 1.26M 2.68M 4.07M 14.75M 20.17M
Long term investments - - - - -
Net tangible assets - - - 9.20M 16.48M
Short term investments - - - - -
Net receivables 0.08M 0.02M 0.06M 0.11M 0.05M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.40M 0.08M 0.20M 1.76M 0.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 1.42M 1.42M 1.40M 1.48M 1.86M
Capital lease obligations 0.04M 0.04M 0.01M 0.08M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03892M -0.04636M -0.04422M -0.03981M
Change to liabilities - - - 1.26M -0.33321M
Total cashflows from investing activities - - - -0.06002M -0.03981M
Net borrowings -0.08957M -0.06972M -0.06609M -0.05513M -0.05513M
Total cash from financing activities 1.43M 2.78M -0.36104M 6.43M 24.46M
Change to operating activities - - - 0.76M -1.00636M
Net income -2.65630M -3.31335M -2.91704M -9.48531M -1.65228M
Change in cash -1.60913M -0.97402M -6.98653M -4.72572M 18.68M
Begin period cash flow 2.47M 3.45M 10.43M 13.89M 0.17M
End period cash flow 0.86M 2.47M 3.45M 10.41M 18.85M
Total cash from operating activities -2.76872M -3.67865M -6.58317M -11.96820M -6.06251M
Issuance of capital stock 2.26M 3.50M 0.00000M 5.05M 22.80M
Depreciation 0.11M 0.12M 0.14M 0.08M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.06253M 0.04M 0.02M -0.05919M -0.03719M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.36961M -0.85611M
Change to netincome - - - -4.52494M -3.05135M
Capital expenditures 0.06M 0.04M 0.05M 0.03M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.34M 0.12M -1.03074M 1.45M -1.37676M
Stock based compensation 0.03M 0.12M 0.12M 0.47M 0.50M
Other non cash items - - - 0.00370M 0.07M
Free cash flow -2.82395M -3.71757M -6.62953M -8.86252M -6.10232M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
XRTX
XORTX Therapeutics Inc		 0.08 2.84% 2.90 - 0.97 - 2.11 -1.5004
SHRX
Sharp Therapeutics Corp.		 - -% 2.10 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.69% 0.58 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.06 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 -0.02 3.33% 0.58 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

XORTX Therapeutics Inc

3710 - 33rd Street NW, Calgary, AB, Canada, T2L 2M1

Key Executives

Name Title Year Born
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, Pres & Director 1960
Mr. Amar Keshri C.A., CPA Chief Financial Officer 1979
Nick Rigopoulos Director of Communications NA
Dr. David Sans M.B.A., Ph.D. Director of Corp. Devel. NA
Dr. Stephen Haworth M.D., MRCP Chief Medical Officer 1951
Dr. David MacDonald Ph.D. Consultant of Clinical Operations 1963
Dr. Stacy Evans M.B.A., M.D. Chief Bus. Officer NA
Ms. Charlotte May Corp. Sec. NA
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, President & Director 1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D Chief Financial Officer 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions